Synthetic cannabinoids (SCs) — marketed as "K2," "Spice," "Cloud 9," "Mojo," and others — are full agonists at CB1 and CB2 receptors with affinities approximately 100 times greater than natural THC (a partial agonist), producing significantly more severe and unpredictable toxicity than cannabis. [1-2] Over 150 compounds have been identified, with new analogs constantly emerging to evade regulation. [2] The typical patient is a young adult male (median age ~35), often with polysubstance use history. [3-4]
1. History
- Substance used: Ask specifically about "K2," "Spice," "herbal incense," "fake weed," paper strips (correctional settings), edible gummies marketed as cannabis [5-6]
- Route: Most commonly smoked/inhaled (onset within minutes, shorter duration than natural cannabis); occasionally ingested [7]
- Timing: Onset typically within minutes of inhalation; duration of effects variable and unpredictable [7]
- Quantity and frequency: Single use vs. chronic daily use (withdrawal risk with chronic use) [8]
- Coingestants: Polysubstance use is common (~31% exposed to >1 substance); ask about opioids, benzodiazepines, alcohol, stimulants [3]
- Source: Internet purchase, head shops, correctional facility paper strips [5][9]
- Prior episodes of SC use or adverse reactions
- Suicidal ideation or self-harm intent (psychiatric presentations are common) [4]
2. Alarm Features
- GCS ≤ 8 — strongly associated with bradycardia and risk of cardiac arrest [5]
- Seizures — generalized tonic-clonic seizures, may be refractory to initial benzodiazepine dosing [4-5]
- Hyperthermia — rapidly life-threatening; exacerbated by physical restraints and ongoing agitation [10-11]
- Cardiac arrest — may present as VF, VT, or PEA [10-11]
- Severe rhabdomyolysis — CPK >320,000 U/L reported; risk of compartment syndrome requiring fasciotomy [12]
- Acute kidney injury — from rhabdomyolysis, direct nephrotoxicity, or dehydration [3-4][12]
- Acute respiratory failure — 60% of ICU-admitted patients in one series; 70% required intubation [7]
- Coma with loss of gray-white differentiation on CT (transient cerebral edema) [7]
- Myocardial infarction — vasospasm-mediated, even in patients with normal coronary arteries [4][10]
- Fulminant hepatic failure — rare but reported, may require liver transplant evaluation [12]
3. Medications
Treatment medications:
- Benzodiazepines — mainstay for agitation, seizures, and prevention of rhabdomyolysis [5][10][13]
- Atropine — for symptomatic bradycardia with hypotension; demonstrated efficacy in SC-specific bradycardia [5]
- Antiemetics — ondansetron for nausea/vomiting [4]
- Antipsychotics — second-generation agents (quetiapine, olanzapine) for psychosis or agitation refractory to benzodiazepines [8][14-15]
- IV fluids — aggressive hydration for rhabdomyolysis and AKI [4-5]
- Ketamine — may be considered for refractory agitation [10]
Medication cautions:
- Avoid prolonged physical restraints without adequate sedation — increases risk of hyperthermia, rhabdomyolysis, and death [10-11]
- No specific antidote exists for SC toxicity [14]
- Standard urine drug screens do NOT detect synthetic cannabinoids — a negative THC screen does not rule out SC use [2][7]
4. Diet
- NPO if altered mental status or risk of aspiration
- Aggressive IV hydration is the priority, particularly with rhabdomyolysis or hyperemesis
- Oral rehydration once mental status clears and patient is tolerating PO
- No specific dietary triggers; however, chronic SC users may present malnourished, particularly undomiciled populations [7]
5. Review of Systems
- Neurologic: Altered consciousness, seizures, hallucinations, tremor, myoclonus, headache [1][4][16]
- Psychiatric: Agitation, paranoia, psychosis, suicidal ideation, catatonia [4][8][17]
- Cardiovascular: Chest pain, palpitations, syncope [4][10]
- GI: Nausea, vomiting, abdominal pain (hyperemesis pattern) [4][18]
- Renal: Decreased urine output, dark urine (rhabdomyolysis) [12]
- Respiratory: Dyspnea, cough (diffuse alveolar hemorrhage reported) [7]
- Musculoskeletal: Muscle rigidity, pain, compartment syndrome symptoms [12]
6. Collateral History and Family History
- Collateral is critical — patients are frequently unable to provide history due to altered mental status [7]
- Obtain information from EMS, bystanders, law enforcement, or correctional officers regarding substance used, packaging, and witnessed events [5]
- Inquire about prior psychiatric history, substance use disorder, and previous SC-related ED visits
- Family history of psychiatric illness (psychosis, bipolar disorder) may increase vulnerability to SC-induced psychiatric complications
- Social context: Homelessness, incarceration, and military/employment drug testing are major risk factors for SC use [5][7][19]
7. Risk Factors
- Young adult males (predominant demographic) [1][3-4]
- Polysubstance use — concurrent opioid, stimulant, or alcohol use [3][6]
- Homelessness — 43% of ICU-admitted patients in one series were undomiciled [7]
- Incarceration — SC-laced paper strips are an emerging route in correctional facilities [5]
- Populations subject to drug testing — SCs are used to evade standard urine drug screens [2][4]
- Prior psychiatric illness or personality disorder [7]
- Low cost and easy availability via internet, head shops, and street sales [9]
8. Differential Diagnosis
- Sympathomimetic toxicity (amphetamines, cathinones, cocaine) — overlapping features of tachycardia, hypertension, agitation, seizures; SCs may present with more CNS depression and bradycardia than classic sympathomimetics [10][20]
- Opioid overdose — CNS depression and bradycardia overlap; consider coingestant; trial of naloxone if respiratory depression present [5]
- Anticholinergic toxicity — agitation, hallucinations, tachycardia; look for dry skin, urinary retention, mydriasis (absent in SC toxicity)
- Serotonin syndrome — agitation, hyperthermia, clonus; medication history is key
- Neuroleptic malignant syndrome — rigidity, hyperthermia, altered mental status; medication history
- Sedative-hypnotic overdose — CNS depression, respiratory failure
- Primary psychiatric emergency — first-episode psychosis, acute mania; SC use may be the precipitant [4]
- Meningitis/encephalitis — fever, altered mental status, seizures; consider LP if infectious etiology not excluded
- Posterior reversible encephalopathy syndrome (PRES) — reported with ADB-CHMINACA; headache, seizures, visual changes [21]
Key distinguishing feature: SC toxicity should be suspected in patients with undifferentiated psychomotor depression and bradycardia with a negative standard tox screen, particularly in young males, incarcerated individuals, or undomiciled patients. [7][20]
9. Past Medical History
- Prior SC or other substance use episodes
- Psychiatric history: psychosis, depression, anxiety, personality disorders [7]
- Seizure disorder (lowers threshold for SC-induced seizures)
- Chronic kidney disease (increased vulnerability to AKI)
- Cardiac history (increased risk of MI, arrhythmia)
- Prior rhabdomyolysis episodes
- Hepatic disease (rare fulminant hepatic failure reported) [12]
10. Physical Exam
Vital signs:
- Tachycardia (37–77% of presentations) OR bradycardia (especially with newer full-agonist compounds — 24% in one series) [4][20]
- Hypertension or hypotension (10% with SBP <90 mmHg) [16][20]
- Hyperthermia or rarely hypothermia [5][10]
- Tachypnea or respiratory depression
Focused exam:
- Neurologic: GCS assessment, pupil size and reactivity (variable — not reliably mydriatic or miotic), tremor, myoclonus, clonus, focal deficits (stroke) [6][21]
- Psychiatric: Level of agitation (Richmond Agitation-Sedation Scale), psychosis assessment, catatonia screening [17]
- Cardiovascular: Rate, rhythm, murmurs, signs of heart failure
- Musculoskeletal: Compartment assessment (tense compartments, pain with passive stretch) — especially with severe rhabdomyolysis [12]
- Skin: Diaphoresis, temperature, signs of IV drug use
- Abdomen: Tenderness (hyperemesis, hepatic injury)
11. Lab Studies
- BMP/CMP — creatinine (AKI), potassium, glucose (hyperglycemia common), hepatic function [12][16]
- CPK — rhabdomyolysis screening; levels can exceed 320,000 U/L [12]
- Urinalysis — myoglobinuria
- Troponin — myocardial injury (elevated in ~50% of critically ill patients) [12]
- Lactate — metabolic acidosis assessment
- VBG/ABG — acidosis (metabolic and/or respiratory) [6]
- CBC — leukocytosis; rare immune thrombocytopenic purpura reported [1]
- Coagulation studies — some SC products have been adulterated with brodifacoum (superwarfarin), causing coagulopathy
- Standard urine drug screen — will be negative for SCs; useful to identify coingestants [7]
- Specialized SC immunoassay or LC-MS/MS — available at some centers with short turnaround times; not widely available for point-of-care [2-3]
- Serum potassium — hypokalemia is characteristic of SC toxicity [16]
12. Imaging
- Chest X-ray — if respiratory distress; may show diffuse pulmonary infiltrates, tree-in-bud pattern, or findings mimicking organizing pneumonia [7]
- CT head — if prolonged altered mental status, focal neurologic deficits, or seizures; may show transient cerebral edema with loss of gray-white differentiation, or PRES [7][21]
- MRI brain — if PRES suspected (posterior white matter edema) [21]
- CT chest — if concern for diffuse alveolar hemorrhage
- Imaging is not routinely necessary for mild presentations that resolve with supportive care
13. Special Tests
- Point-of-care glucose — hyperglycemia is common [16]
- Point-of-care lactate — rapid assessment of metabolic acidosis
- Bedside ultrasound — cardiac function assessment if hemodynamically unstable (takotsubo cardiomyopathy) [10]
- Bush-Francis Catatonia Rating Scale — if catatonia suspected [17]
- Specialized toxicology testing — liquid chromatography–high resolution mass spectrometry (LC-HRMS) is the gold standard for SC identification and confirmation; typically send-out only [2]
- Poison Control consultation — recommended for severe or unusual presentations
14. ECG
- Indications: All patients with SC toxicity should receive an ECG
- Common findings:
- Sinus tachycardia (most common) [4]
- Sinus bradycardia (especially with newer full-agonist compounds) [5][20]
- Dangerous patterns to recognize:
- ST-segment changes — vasospasm-mediated myocardial ischemia/infarction [10]
- QTc prolongation — risk of torsades de pointes
- Ventricular tachycardia / ventricular fibrillation — may present as sudden cardiac arrest [10-11]
- PEA — in cardiac arrest [10]
- Serial ECGs if initial abnormalities or ongoing chest pain
15. Assessment
Synthetic cannabinoid toxicity presents on a spectrum from mild to life-threatening. Most presentations involve young males with tachycardia, agitation, and nausea that resolve within 2–8 hours with supportive care. [4][19] However, newer full-agonist compounds produce more severe and unpredictable toxicity, including profound CNS depression, bradycardia, seizures, and multi-organ failure. [1][5][12]
Severity stratification:
- Mild: Anxiety, tachycardia, nausea, mild agitation — resolves with observation
- Moderate: Persistent agitation, vomiting, seizure, mild rhabdomyolysis — requires active treatment
- Severe/Critical: Coma (GCS ≤8), refractory seizures, cardiac arrest, severe rhabdomyolysis, AKI, respiratory failure, hepatic failure, hyperthermia [7][12]
Atypical presentations include catatonia, posterior reversible encephalopathy syndrome, diffuse alveolar hemorrhage, and coagulopathy from brodifacoum-adulterated products. [7][17][21]
16. Treatment Plan
Initial stabilization (ABCs):
- Airway protection — intubation for GCS ≤8 or respiratory failure (required in up to 70% of ICU patients) [7]
- Continuous cardiac monitoring and pulse oximetry
- IV access, IV fluids
Agitation/Seizures:
- Benzodiazepines first-line — midazolam 5–10 mg IM/IV or lorazepam 2–4 mg IV; repeat as needed [5][10][13]
- Refractory agitation: escalate to propofol or ketamine infusion; consider intubation [5][15]
- Refractory seizures: treat per status epilepticus protocol
- Avoid prolonged physical restraints without sedation [10-11]
Bradycardia with hypotension:
- Atropine 0.5–1 mg IVJAMA Netw Open[5]
Hyperthermia:
- Aggressive external/evaporative cooling; avoid cooling blankets alone (insufficient) [10]
- Benzodiazepines to reduce heat-generating muscle activity
Rhabdomyolysis:
- Aggressive IV crystalloid resuscitation targeting UOP 1–3 mL/kg/hr [5][12]
- Monitor CPK, renal function, electrolytes serially
- Surgical consultation if compartment syndrome suspected [12]
Psychosis:
Cardiac arrest:
17. Disposition
Discharge criteria:
- Mild symptoms resolving within 4–6 hours of observation
- Normal vital signs, normal mental status, ambulating
- Able to tolerate PO, no laboratory abnormalities
- Safe disposition (not suicidal, has follow-up plan)
- Most uncomplicated presentations have ED length of stay <8 hours [4]
Admission criteria (telemetry/floor):
- Persistent vital sign abnormalities (bradycardia, tachycardia, hypertension)
- Mild-moderate rhabdomyolysis requiring IV hydration
- Prolonged altered mental status
- Psychiatric admission for persistent psychosis or suicidality [22]
ICU admission criteria:
- GCS ≤8 or intubation required [7]
- Refractory seizures
- Severe rhabdomyolysis (CPK >10,000 or rising) with AKI [12]
- Hemodynamic instability requiring vasopressors or atropine
- Respiratory failure
- Cardiac arrest or significant arrhythmia
- Hepatic failure [12]
Specialist consultation triggers:
- Toxicology/Poison Control — all moderate-severe cases
- Nephrology — AKI requiring CRRT [12]
- Surgery — compartment syndrome [12]
- Hepatology/Transplant — fulminant hepatic failure [12]
- Psychiatry — persistent psychosis, catatonia, suicidality [17][22]
18. Follow Up / Return Precautions
Follow-up timing:
- PCP or urgent care within 48–72 hours for discharged patients
- Repeat BMP/CPK within 24–48 hours if rhabdomyolysis was present
- Psychiatry follow-up if psychiatric symptoms were prominent
- Substance use disorder referral and counseling at discharge [8]
Return precautions — instruct patient to return immediately for:
- Recurrent seizures
- Chest pain, palpitations, or syncope
- Dark or decreased urine output
- Worsening confusion, agitation, or hallucinations
- Fever
- Muscle pain or swelling (compartment syndrome)
- Suicidal thoughts
Patient counseling:
- SCs are not safe alternatives to cannabis — they are far more potent and unpredictable [1-2]
- Standard drug tests do not detect SCs, but this does not make them "safe" [7]
- Chronic use leads to dependence; withdrawal symptoms include anxiety, insomnia, irritability, and diaphoresis [8]
- Products are unregulated — composition varies batch to batch, and adulterants (including opioids, brodifacoum) are common [5-6]
- Expected recovery: mild cases resolve within hours; severe cases (AKI, rhabdomyolysis, hepatic injury) may require weeks of recovery [4][12]
References
1. Adverse Clinical Effects Associated With the Use of Synthetic Cannabinoids: A Systematic Review. — Prete MM, Feitosa GTB, Ribeiro MAT, Fidalgo TM, Sanchez ZM. Drug and Alcohol Dependence. 2025.
2. Adverse Clinical Effects Associated With the Use of Synthetic Cannabinoids: A Systematic Review. — Prete MM, Feitosa GTB, Ribeiro MAT, Fidalgo TM, Sanchez ZM. Drug and Alcohol Dependence. 2025.
3. Adverse Clinical Effects Associated With the Use of Synthetic Cannabinoids: A Systematic Review. — Prete MM, Feitosa GTB, Ribeiro MAT, Fidalgo TM, Sanchez ZM. Drug and Alcohol Dependence. 2025.
4. Intoxication From the Novel Synthetic Cannabinoids AB-PINACA and ADB-PINACA: A Case Series and Review of the Literature. — Armenian P, Darracq M, Gevorkyan J, et al. Neuropharmacology. 2018.
5. Intoxication From the Novel Synthetic Cannabinoids AB-PINACA and ADB-PINACA: A Case Series and Review of the Literature. — Armenian P, Darracq M, Gevorkyan J, et al. Neuropharmacology. 2018.
6. Acute Intoxication Caused by Three Common Synthetic Cannabinoids: The Experience of a Large, Urban, Tertiary Care Hospital. — Shopan N, Scolnik D, Hassoun E, et al. The American Journal of Emergency Medicine. 2023.
7. Acute Intoxication Caused by Three Common Synthetic Cannabinoids: The Experience of a Large, Urban, Tertiary Care Hospital. — Shopan N, Scolnik D, Hassoun E, et al. The American Journal of Emergency Medicine. 2023.
8. A Systematic Review of Adverse Events Arising From the Use of Synthetic Cannabinoids and Their Associated Treatment. — Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. Clinical Toxicology. 2015.
9. A Systematic Review of Adverse Events Arising From the Use of Synthetic Cannabinoids and Their Associated Treatment. — Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. Clinical Toxicology. 2015.
10. Identification and Health Risks of an Emerging Means of Drug Use in Correctional Facilities. — Kuai D, Rivera Blanco LE, Krotulski A, et al. JAMA Network Open. 2024.
11. Identification and Health Risks of an Emerging Means of Drug Use in Correctional Facilities. — Kuai D, Rivera Blanco LE, Krotulski A, et al. JAMA Network Open. 2024.
12. Clinical Features Associated With ADB-BUTINACA Exposure in Patients Attending Emergency Departments in England. — King A, Hill SL, Pucci M, et al. Clinical Toxicology. 2022.
13. Clinical Features Associated With ADB-BUTINACA Exposure in Patients Attending Emergency Departments in England. — King A, Hill SL, Pucci M, et al. Clinical Toxicology. 2022.
14. Critical Illness Secondary to Synthetic Cannabinoid Ingestion. — Kourouni I, Mourad B, Khouli H, Shapiro JM, Mathew JP. JAMA Network Open. 2020.
15. Critical Illness Secondary to Synthetic Cannabinoid Ingestion. — Kourouni I, Mourad B, Khouli H, Shapiro JM, Mathew JP. JAMA Network Open. 2020.
16. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal. — Cooper ZD. Current Psychiatry Reports. 2016.
17. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal. — Cooper ZD. Current Psychiatry Reports. 2016.
18. Synthetic Cannabinoids. — Mills B, Yepes A, Nugent K. The American Journal of the Medical Sciences. 2015.
19. Synthetic Cannabinoids. — Mills B, Yepes A, Nugent K. The American Journal of the Medical Sciences. 2015.
20. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Lavonas EJ, Akpunonu PD, Arens AM, et al. Circulation. 2023.
21. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Lavonas EJ, Akpunonu PD, Arens AM, et al. Circulation. 2023.
22. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.
23. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.
24. Synthetic Cannabinoid-Associated Multiple Organ Failure: Case Series and Literature Review. — Armstrong F, McCurdy MT, Heavner MS. Pharmacotherapy. 2019.
25. Synthetic Cannabinoid-Associated Multiple Organ Failure: Case Series and Literature Review. — Armstrong F, McCurdy MT, Heavner MS. Pharmacotherapy. 2019.
26. Pharmacotherapy of Patients Taking New Psychoactive Substances: A Systematic Review and Analysis of Case Reports. — Ordak M, Zmysłowska A, Bielski M, et al. Frontiers in Psychiatry. 2021.
27. Pharmacotherapy of Patients Taking New Psychoactive Substances: A Systematic Review and Analysis of Case Reports. — Ordak M, Zmysłowska A, Bielski M, et al. Frontiers in Psychiatry. 2021.
28. Cannabis-Related Disorders and Toxic Effects. — Gorelick DA. The New England Journal of Medicine. 2023.
29. Cannabis-Related Disorders and Toxic Effects. — Gorelick DA. The New England Journal of Medicine. 2023.
30. New Drugs of Abuse. — Rech MA, Donahey E, Cappiello Dziedzic JM, Oh L, Greenhalgh E. Pharmacotherapy. 2015.
31. New Drugs of Abuse. — Rech MA, Donahey E, Cappiello Dziedzic JM, Oh L, Greenhalgh E. Pharmacotherapy. 2015.
32. Acute Toxicity Due to the Confirmed Consumption of Synthetic Cannabinoids: Clinical and Laboratory Findings. — Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Addiction. 2013.
33. Acute Toxicity Due to the Confirmed Consumption of Synthetic Cannabinoids: Clinical and Laboratory Findings. — Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Addiction. 2013.
34. Catatonia Secondary to Synthetic Cannabinoid Use in Two Patients With No Previous Psychosis. — Khan M, Pace L, Truong A, Gordon M, Moukaddam N. The American Journal on Addictions. 2016.
35. Catatonia Secondary to Synthetic Cannabinoid Use in Two Patients With No Previous Psychosis. — Khan M, Pace L, Truong A, Gordon M, Moukaddam N. The American Journal on Addictions. 2016.
36. Synthetic Cannabinoid Hyperemesis Resulting in Rhabdomyolysis and Acute Renal Failure. — Argamany JR, Reveles KR, Duhon B. The American Journal of Emergency Medicine. 2016.
37. Synthetic Cannabinoid Hyperemesis Resulting in Rhabdomyolysis and Acute Renal Failure. — Argamany JR, Reveles KR, Duhon B. The American Journal of Emergency Medicine. 2016.
38. Evolution of Clinical Characteristics and Outcomes of Synthetic Cannabinoid Receptor Agonist Exposure in the United States: Analysis of National Poison Data System Data From 2010 to 2015. — Cordeiro SK, Daro RC, Seung H, Klein-Schwartz W, Kim HK. Addiction. 2018.
39. Evolution of Clinical Characteristics and Outcomes of Synthetic Cannabinoid Receptor Agonist Exposure in the United States: Analysis of National Poison Data System Data From 2010 to 2015. — Cordeiro SK, Daro RC, Seung H, Klein-Schwartz W, Kim HK. Addiction. 2018.
40. Retrospective Chart Review of Synthetic Cannabinoid Intoxication With Toxicologic Analysis. — Sud P, Gordon M, Tortora L, et al. The Western Journal of Emergency Medicine. 2018.
41. Retrospective Chart Review of Synthetic Cannabinoid Intoxication With Toxicologic Analysis. — Sud P, Gordon M, Tortora L, et al. The Western Journal of Emergency Medicine. 2018.
42. Acute Toxicity of ADB-CHMINACA - A Case Series of Patients With Pronounced Central Nervous Symptoms Including the Posterior Reversible Encephalopathic Syndrome. — Hermanns-Clausen M, Sommer M, Zschiesche A, et al. British Journal of Clinical Pharmacology. 2026.
43. Acute Toxicity of ADB-CHMINACA - A Case Series of Patients With Pronounced Central Nervous Symptoms Including the Posterior Reversible Encephalopathic Syndrome. — Hermanns-Clausen M, Sommer M, Zschiesche A, et al. British Journal of Clinical Pharmacology. 2026.
44. Clinical Effects of Cannabis Compared to Synthetic Cannabinoid Receptor Agonists (SCRAs): A Retrospective Cohort Study of Presentations With Acute Toxicity to European Hospitals Between 2013 and 2020. — Waters ML, Dargan PI, Yates C, et al. Clinical Toxicology. 2024.
45. Clinical Effects of Cannabis Compared to Synthetic Cannabinoid Receptor Agonists (SCRAs): A Retrospective Cohort Study of Presentations With Acute Toxicity to European Hospitals Between 2013 and 2020. — Waters ML, Dargan PI, Yates C, et al. Clinical Toxicology. 2024.